KELOWNA, BC – Lexaria Bioscience Corp. (the “Company” or “Lexaria“), a global innovator in drug delivery platforms, is pleased to announce successful results from its fluorescently tagged semaglutide (“FTS“) rodent biodistribution… Read More
Pending the European Commission’s final decision, nipocalimab could be the first FcRn blocker approved in both adult and adolescent gMG patients aged 12 and older who are anti-AChR or anti-MuSK… Read More
Idorsia receives approval from Swissmedic for JERAYGO™ (aprocitentan) as the first and only endothelin receptor antagonist (ERA) for the treatment of resistant hypertension. JERAYGO is a new oral antihypertensive therapy –… Read More
Researchers are learning how what we eat affects the gut and influences conditions like kidney stone formation. Kidney stone disease has been on the rise in Canada over the past 25… Read More
National Advocacy Platform will Champion Patient Access and Health Innovation Ottawa, – Innovative Medicines Canada (IMC) is proud to announce the official launch of Medicine Matters Canada, a new national… Read More
